Moderna announces bivalent booster mrna-1273.214 demonstrates potent neutralizing antibody response against omicron subvariants ba.4 and ba.5

Mrna-1273.214 exhibited a greater than 5-fold boost in neutralizing antibodies against ba.4 and ba.5 subvariants in phase 2/3 study data being submitted to regulators and for peer reviewed publication cambridge, ma / accesswire / june 22, 2022 / moderna, inc., (nasdaq:mrna) a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced new clinical data on its bivalent (omicron) covid booster candidate, mrna-1273.214. one month after administration in previously vaccinated and boosted participants, a 50 Μg booster dose of mrna-1273.214 elicited potent neutralizing antibody responses against the omicron subvariants ba.4 and ba.5 in all participants regardless of prior infection.
MRNA Ratings Summary
MRNA Quant Ranking